A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).

Authors

Vaibhav Sahai

University of Michigan, Ann Arbor, MI

Vaibhav Sahai , Amy E. Chang , Oxana V. Crysler , David Bing Zhen , Muhammad Shaalan Beg , Timothy S. Pardee , Sanjeev Luther , Kent A. Griffith , Mark Zalupski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.

First Author: Zhen-gang Yuan

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).

First Author: Vaibhav Sahai

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.

First Author: Vaibhav Sahai

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.

First Author: Vaibhav Sahai